Blueprint Medicines Corporation (BPMC): Price and Financial Metrics


Blueprint Medicines Corporation (BPMC)

Today's Latest Price: $79.15 USD

0.13 (0.16%)

Updated Jul 2 4:00pm

Add BPMC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

BPMC Stock Summary

  • Of note is the ratio of Blueprint Medicines Corp's sales and general administrative expense to its total operating expenses; just 12.88% of US stocks have a lower such ratio.
  • With a price/sales ratio of 58.75, Blueprint Medicines Corp has a higher such ratio than 96.41% of stocks in our set.
  • Revenue growth over the past 12 months for Blueprint Medicines Corp comes in at 62.42%, a number that bests 91.52% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Blueprint Medicines Corp, a group of peers worth examining would be AGIO, PRNB, RARE, TBIO, and SYRS.
  • BPMC's SEC filings can be seen here. And to visit Blueprint Medicines Corp's official web site, go to www.blueprintmedicines.com.
BPMC Daily Price Range
BPMC 52-Week Price Range

BPMC Stock Price Chart Technical Analysis Charts


BPMC Price/Volume Stats

Current price $79.15 52-week high $102.98
Prev. close $79.02 52-week low $43.29
Day low $78.51 Volume 269,920
Day high $80.92 Avg. volume 767,645
50-day MA $68.69 Dividend yield N/A
200-day MA $69.48 Market Cap 4.29B

Blueprint Medicines Corporation (BPMC) Company Bio


Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.


BPMC Latest News Stream


Event/TimeNews Detail
Loading, please wait...

BPMC Latest Social Stream


Loading social stream, please wait...

View Full BPMC Social Stream

Latest BPMC News From Around the Web

Below are the latest news stories about Blueprint Medicines Corp that investors may wish to consider to help them evaluate BPMC as an investment opportunity.

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on July 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 30,778 shares of its common stock and an aggregate of 15,388 restricted stock units (RSUs) to 13 new employees under Blueprint Medicines' 2020 Inducement Plan.

Yahoo | July 2, 2020

Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC

Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.

Yahoo | July 2, 2020

Blueprint Medicines files U.S. application for pralsetinib for thyroid cancer

Blueprint Medicines (BPMC) has submitted a marketing application to the FDA seeking approval of RET inhibitor pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancers.The filing was made under the agency's Real-Time Oncology Review pilot program.The company's applications for RET-altered...

Seeking Alpha | July 1, 2020

Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pralsetinib for the treatment of patients with advanced or metastatic RET mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancers. Pralsetinib is an investigational, once-daily precision therapy designed to potently and selectively inhibit RET fusions and mutations, including predicted resistance mutations.

Yahoo | July 1, 2020

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST

CAMBRIDGE, Mass. , June 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC ), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that The Lancet Oncology published data from the NAVIGATOR clinical trial showing an unprecedented overall survival (OS) rate and a well -tolerated safety profile for AYVAKIT™ (avapritinib) in patients with advanced PDGFRA D842V mutant gastrointestinal stromal tumor (GIST). The paper, titled "Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial," was published online in The Lancet Oncology on June 29, 2020 . "The data published in The Lancet Oncology show that patients with PDGFRA D842V mutant...

Benzinga Feeds | June 29, 2020

Read More 'BPMC' Stories Here

BPMC Price Returns

1-mo 11.21%
3-mo 21.28%
6-mo -1.43%
1-year -17.37%
3-year 48.28%
5-year 207.98%
YTD -1.20%
2019 48.60%
2018 -28.51%
2017 168.84%
2016 6.49%
2015 N/A

Continue Researching BPMC

Want to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:

Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8665 seconds.